Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$0.87 - $1.71 $1.24 Million - $2.44 Million
-1,427,989 Reduced 13.62%
9,059,839 $15.5 Million
Q2 2023

Aug 14, 2023

BUY
$0.83 - $1.18 $6.25 Million - $8.88 Million
7,525,493 Added 254.04%
10,487,828 $12.1 Million
Q1 2023

May 15, 2023

BUY
$0.8 - $4.98 $1.03 Million - $6.43 Million
1,291,964 Added 77.35%
2,962,335 $2.4 Million
Q4 2022

Feb 14, 2023

BUY
$1.88 - $36.45 $1.44 Million - $27.9 Million
766,063 Added 84.71%
1,670,371 $3.98 Million
Q3 2022

Nov 14, 2022

BUY
$2.5 - $37.95 $160,190 - $2.43 Million
64,076 Added 7.63%
904,308 $2.05 Million
Q2 2022

Aug 15, 2022

BUY
$1.75 - $11.34 $1.06 Million - $6.85 Million
603,858 Added 255.47%
840,232 $2.06 Million
Q1 2022

May 13, 2022

BUY
$10.21 - $20.29 $245,867 - $488,603
24,081 Added 11.34%
236,374 $2.41 Million
Q4 2021

Feb 14, 2022

SELL
$16.76 - $22.99 $3.35 Million - $4.6 Million
-199,999 Reduced 48.51%
212,293 $4.18 Million
Q3 2021

Nov 15, 2021

SELL
$13.15 - $22.56 $2,051 - $3,519
-156 Reduced 0.04%
412,292 $7.62 Million
Q2 2021

Aug 16, 2021

SELL
$18.28 - $33.05 $1.13 Million - $2.05 Million
-62,008 Reduced 13.07%
412,448 $7.54 Million
Q1 2021

May 18, 2021

SELL
$29.34 - $60.2 $2.93 Million - $6.02 Million
-100,000 Reduced 17.41%
474,456 $15.5 Million
Q4 2020

Feb 18, 2021

BUY
$27.25 - $55.82 $15.7 Million - $32.1 Million
574,456 New
574,456 $31.6 Million

Others Institutions Holding PRAX

# of Institutions
1
Shares Held
75K
Call Options Held
0
Put Options Held
0

About Praxis Precision Medicines, Inc.


  • Ticker PRAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,576,100
  • Market Cap $3.54B
  • Description
  • Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...
More about PRAX
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.